Hypnotic

The hypnotic class comprises substances that induce or maintain sleep. While overlapping substantially with depressants and sedatives, hypnotics are distinguished by their primary therapeutic application: the promotion of sleep onset and sleep maintenance.

The general hypnotic experience involves a progressive drowsiness that deepens over fifteen to sixty minutes into an irresistible pull toward sleep. The mind slows. Thoughts become fragmented and dream-like. The body relaxes and becomes heavy. The transition from wakefulness to sleep is smoothed and accelerated. Depending on the specific compound, sleep may be lighter or deeper than natural sleep, and the architecture of sleep stages may be altered.

Side effects vary by compound but may include next-day grogginess, impaired memory formation for events occurring after dosing, and complex sleep behaviors such as sleepwalking, sleep-eating, or sleep-driving. The class includes benzodiazepines, z-drugs, barbiturates, antihistamines, and melatonin receptor agonists.

Hypnotic drugs produce sleep or sleep-like states through multiple distinct mechanisms depending on drug class.

Benzodiazepines (diazepam, triazolam, temazepam, nitrazepam) bind to the benzodiazepine modulatory site on GABA-A receptors — pentameric ligand-gated chloride channels — and act as positive allosteric modulators. They enhance the effect of GABA without directly opening the channel, increasing the frequency of chloride channel opening. This potentiates inhibitory neurotransmission throughout the CNS. Different benzodiazepines have varying affinities for GABA-A receptor subunit compositions (particularly gamma subunits), accounting for differences in hypnotic versus anxiolytic versus anticonvulsant selectivity.

Z-drugs (zolpidem, zaleplon, eszopiclone, zopiclone) also act at GABA-A receptors but with greater selectivity for alpha-1 subunit-containing receptors compared to benzodiazepines. Alpha-1 GABA-A receptors mediate sedation and anterograde amnesia; alpha-2 and alpha-3 mediate anxiolysis and muscle relaxation. This selectivity was hypothesized to make Z-drugs safer, though real-world evidence has not fully supported this distinction.

Barbiturates (phenobarbital, secobarbital) act at the same GABA-A receptor site but are full agonists at higher doses — they can directly open the chloride channel even without GABA. This mechanism causes the narrow therapeutic window and high overdose lethality that led to their replacement by benzodiazepines.

Antihistamines (diphenhydramine, doxylamine) produce sedation through H1 receptor antagonism; they are first-generation antihistamines that cross the blood-brain barrier and block histaminergic wakefulness-promoting circuits.

Melatonin receptor agonists (ramelteon, tasimelteon) activate MT1/MT2 receptors in the suprachiasmatic nucleus, shifting circadian phase rather than directly inducing sedation, and are uniquely non-habit-forming.

Orexin antagonists (suvorexant, lemborexant) block orexin (hypocretin) OX1R and OX2R receptors, preventing wakefulness-promoting orexin signaling — a mechanism directly opposite to the orexin deficiency seen in narcolepsy.

Alcohol is the oldest hypnotic, with deliberate use for sleep promotion documented across ancient civilizations. Opium (laudanum preparations) served as the dominant sedative-hypnotic until the 19th century, with all the addiction and toxicity implications this entailed.

Chloral hydrate, synthesized in 1832, became the first synthetic hypnotic in widespread medical use. Its infamy was cemented by its use in the "Mickey Finn" — drinks spiked with chloral hydrate to incapacitate victims. Bromide salts were also used extensively in the late 19th century despite causing "bromism" (chronic toxicity syndrome) with long-term use.

Barbiturates were synthesized beginning in 1864 (barbituric acid) and developed clinically from 1903 (barbital, veronal) through the early 20th century. By the 1950s, barbiturates like secobarbital and amobarbital were among the most prescribed drugs in the world, and barbiturate overdose (often deliberate) was a major cause of mortality. Marilyn Monroe's death in 1962 from barbiturate overdose was emblematic of this era.

Benzodiazepines were discovered accidentally by Leo Sternbach at Hoffmann-La Roche in 1955 during a compound library screen. Chlordiazepoxide (Librium) was approved in 1960, followed by diazepam (Valium) in 1963. Valium became the best-selling pharmaceutical in the US from 1968 to 1982, nicknamed "Mother's little helper" after the Rolling Stones song. Their apparent safety advantage over barbiturates led to mass prescribing before their dependence and withdrawal risks were fully appreciated.

Z-drugs entered the market in the 1990s (zolpidem/Ambien 1992, zaleplon 1999, eszopiclone 2004) with claims of improved safety. Orexin antagonists (suvorexant, 2014; lemborexant, 2019) represent the most mechanistically novel hypnotics approved in recent decades, acting on the wakefulness system rather than the sleep system.